Drawing for FLUOTAG

USPTO serial 87372427

FLUOTAG

Reviewed by CopyMark Law Group

Reg. 5441584Status 702Registered
Filing date
Status date
Registration date
Apr 10, 2018
Examiner
LOTT, MAUREEN DALL
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with FLUOTAG?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ryan D. Artis

Ryan D. Artis RIVERSIDE LAW LLP175 Strafford AveSuite 100WAYNE, PA 19087

Goods and services

ClassDescriptionStatusFirst use
001Chemical reagents for scientific or industrial purposes and not for medical or veterinary use, namely, chemical reagents containing antibodies or proteins having antibody-like properties; Chemical reagents for scientific or industrial purposes and not for medical or veterinary use, namely, for microscopy, flow cytometry, western blot, imaging, fluorescence based analysis, or tissue analysis; Diagnostic or analytical kits other than for medical or veterinary use containing chemical reagents containing antibodies or proteins having antibody-like properties; Diagnostic or analytical kits other than for medical or veterinary use containing chemical reagents for microscopy, flow cytometry, western blot, imaging, fluorescence based analysis, or tissue analysisACTIVE—
005Pharmaceutical and veterinary preparations containing antibodies, all for use in treating cancer; Pharmaceutical and veterinary preparations containing antibodies, all for use in treating autoimmune diseases; Pharmaceutical and veterinary preparations containing antibodies, all for use in treating infectious diseases; Pharmaceutical and veterinary preparations containing antibodies, all for use in treating inflammatory diseases; Pharmaceutical and veterinary preparations containing proteins having antibody-like properties, all for use in treating cancer; Pharmaceutical and veterinary preparations containing proteins having antibody-like properties, all for use in treating autoimmune diseases; Pharmaceutical and veterinary preparations containing proteins having antibody-like properties, all for use in treating infectious diseases; Pharmaceutical and veterinary preparations containing proteins having antibody-like properties, all for use in treating inflammatory diseases; Diagnostic preparations for medical or veterinary purposes, namely preparations containing antibodies or proteins having antibody-like properties [ ; Drugs being pharmaceutical preparations containing antibodies, all for use in treating cancer; Drugs being pharmaceutical preparations containing antibodies, all for use in treating autoimmune diseases; Drugs being pharmaceutical preparations containing antibodies, all for use in treating infectious diseases; Drugs being pharmaceutical preparations containing antibodies, all for use in treating inflammatory diseases; Drugs being pharmaceutical preparations containing proteins having antibody-like properties, all for use in treating cancer; Drugs being pharmaceutical preparations containing proteins having antibody-like properties, all for use in treating autoimmune diseases; Drugs being pharmaceutical preparations containing proteins having antibody-like properties, all for use in treating infectious diseases; Drugs being pharmaceutical preparations containing proteins having antibody-like properties, all for use in treating inflammatory diseases; Vaccines containing antibodies; Vaccines containing proteins having antibody-like properties ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 30, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 30, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 26, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 22, 2024E815TEAS SECTION 8 & 15 RECEIVED—
Apr 10, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Apr 10, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 23, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 23, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 3, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 7, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 7, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 7, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 7, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 9, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 8, 2017DOCKASSIGNED TO EXAMINER—
Mar 21, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 18, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance